MedTrace Logo

Comparison Study of PF530 and Betaferon in Healthy Subjects

NCT02474134 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-11-16

No results posted yet for this study

Summary

The purpose of this study is to compare the safety, tolerability, and blood levels of two interferon beta-1b products, Betaferon and PF530, in healthy volunteers.

Conditions

Interventions

DRUG

Interferon beta-1b (PF530, Betaferon)

Single subcutaneous administration

Sponsors & Collaborators

  • Pfenex, Inc

    lead INDUSTRY

Principal Investigators

  • Sepehr Shakib, MD · CMAX, A Division of IDT Australia, Limited

  • Hubert C Chen, MD · Pfenex, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474134 on ClinicalTrials.gov